Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:27:37 EDT Tue 21 Jul 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:TARS - TARSUS PHARMACEUTICALS INC - http://www.tarsis.ca
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TARS - Q3.556.15·58.383.457.26+1.011.81,042.958,61810,89255.24  57.785  55.2485.25  38.5117:53:16Jul 1315 min RT 2¢

Recent Trades - Last 10 of 10892
Time ETExPriceChangeVolume
17:53:16Q57.671.4215
16:49:08Q57.261.0180,843
16:26:06Q58.141.894
16:25:52Q57.861.619
16:10:04Q57.261.011
16:10:04Q57.261.011
16:10:04Q57.261.011
16:10:04Q57.261.011
16:04:44Q57.261.011
16:04:44Q57.261.011

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-13 16:05U:TARSNews ReleaseTarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
2026-07-08 16:05U:TARSNews ReleaseTarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
2026-06-02 08:30U:TARSNews ReleaseAchieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
2026-05-28 16:30U:TARSNews ReleaseTarsus to Participate in Upcoming Investor Conferences
2026-05-14 08:30U:TARSNews ReleaseTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
2026-05-07 17:00U:TARSNews ReleaseTarsus to Participate in Upcoming Investor Conferences
2026-05-06 16:05U:TARSNews ReleaseTarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
2026-04-29 16:30U:TARSNews ReleaseTarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
2026-03-31 08:30U:TARSNews ReleaseTarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
2026-03-23 08:30U:TARSNews ReleaseTP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
2026-02-26 16:30U:TARSNews ReleaseTarsus to Participate in Upcoming Investor Conferences
2026-02-23 16:05U:TARSNews ReleaseTarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
2026-02-18 08:30U:TARSNews ReleaseTarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
2026-02-17 16:30U:TARSNews ReleaseTarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
2025-11-24 16:30U:TARSNews ReleaseTarsus to Participate in Upcoming Investor Conference
2025-11-05 17:05U:TARSNews ReleaseTarsus to Participate in Upcoming Investor Conference
2025-11-04 16:05U:TARSNews ReleaseTarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
2025-10-28 17:00U:TARSNews ReleaseTarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
2025-08-27 17:00U:TARSNews ReleaseTarsus to Participate in Upcoming Investor Conferences
2025-08-06 16:05U:TARSNews ReleaseTarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements